Some dopaminergic genes polymorphisms are not associated with response to antipsychotic drugs in schizophrenic patients

• Published in: Pharmacological reports Vol. 64; no. 3; pp. 528 - 535
• Main Authors: Tybura, Piotr, Samochowiec, Agnieszka, Beszlej, Aleksander, Grzywacz, Anna, Mak, Monika, Frydecka, Dorota, Bieńkowski, Przemysław, Mierzejewski, Paweł, Potemkowski, Andrzej, Samochowiec, Jerzy
• Format: Journal Article
• Language: English
• Published: Cham Elsevier Urban & Partner Sp. z o.o 2012; Springer International Publishing
• Subjects: Adult; Antipsychotic Agents - therapeutic use; Benzodiazepines - therapeutic use; Dopamine - metabolism; Dopamine Antagonists - therapeutic use; Drug Safety and Pharmacovigilance; Female; Follow-Up Studies; Genotype; Humans; Male; Middle Aged; Olanzapine; perazine; Perazine - therapeutic use; pharmacogenetics; Pharmacotherapy; Pharmacy; Piperazines - therapeutic use; Polymorphism, Genetic; schizophrenia; Schizophrenia, Paranoid - drug therapy; Schizophrenia, Paranoid - genetics; Thiazoles - therapeutic use; Time Factors; Treatment Outcome; Young Adult; ziprasidone; olanzapine; schizophrenia; perazine; ziprasidone; pharmacogenetics; atypical neuroleptics; typical

Therapeutic effects of all clinically used antipsychotics are related to the reduction of dopaminergic transmission in the limbic system. The aim of present study was two-fold. First, efficacy of atypical drugs (ziprasidone and olanzapine) against schizophrenia symptoms was compared to that offered...